Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma

被引：0
|
作者：
M Ladetto
S Ferrero
D Drandi
M Festuccia
F Patriarca
N Mordini
S Cena
R Benedetto
G Guarona
F Ferrando
L Brunello
P Ghione
V Boccasavia
R Fanin
P Omedè
L Giaccone
A Palumbo
R Passera
M Boccadoro
B Bruno
机构：
[1] A.O.U. Città della Salute e della Scienza di Torino,Division of Hematology
[2] University of Torino,Department of Molecular Biotechnology and Health Sciences
[3] University of Torino,Division of Hematology
[4] Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo,Division of Hematology
[5] A.O.U,Division of Nuclear Medicine
[6] Udine,undefined
[7] DISM,undefined
[8] University of Udine,undefined
[9] Ospedale ‘S.Croce e Carle’,undefined
[10] Statistical Consultant,undefined
[11] A.O.U. Città della Salute e della Scienza di Torino,undefined
来源：
Leukemia | 2016年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1211 / 1214
页数：3
相关论文
共 50 条
  • [31] Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
    Wang, Jing
    Li, Jing
    Zhang, Run
    Li, Jianyong
    Chen, Lijuan
    Jin, Yuanyuan
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [32] Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
    Jing Wang
    Jing Li
    Run Zhang
    Jianyong Li
    Lijuan Chen
    Yuanyuan Jin
    Discover Oncology, 15
  • [33] Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma
    Boeckle, David
    Tabares, Paula
    Zhou, Xiang
    Schimanski, Sven
    Steinhardt, Maximilian J.
    Bittrich, Max
    Seebacher, Elena
    Ulbrich, Maria
    Wilnit, Amy
    Metz, Corona
    Heidemeier, Anke
    Bley, Thorsten
    Werner, Rudolf
    Buck, Andreas
    Einsele, Hermann
    Kortuem, K. Martin
    Beilhack, Andreas
    Rasche, Leo
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : 515 - 522
  • [34] MINIMAL RESIDUAL DISEASE (MRD) RATIO BEFORE AND AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
    Antonioli, E.
    Nozzoli, C.
    Staderini, M.
    Boncompagni, R.
    Caporale, R.
    Peruzzi, B.
    Bosi, A.
    Saccardi, R.
    HAEMATOLOGICA, 2019, 104 : 66 - 66
  • [35] Planned sequential autologous/non-myeloablative allogeneic peripheral stem cell transplantation in patients with newly diagnosed high-risk multiple myeloma
    Zinke-Cerwenka, W
    Neumeister, P
    Eibl, M
    Sill, H
    Emberger, W
    Wagner, T
    Wölfler, A
    Linkesch, W
    BONE MARROW TRANSPLANTATION, 2005, 35 : S387 - S388
  • [36] Cytofluorimetric monitoring of minimal residual disease can predict clinical remission in multiple myeloma patients undergoing non myeloablative allogeneic transplantation.
    Omede, P
    Bruno, B
    Giaretta, F
    Ladetto, M
    Battaglio, I
    Ruggeri, M
    Di Bello, C
    Morrone, F
    Aitoro, G
    Rotta, M
    Boccadoro, M
    BLOOD, 2002, 100 (11) : 375B - 375B
  • [37] Non-myeloablative allograft to induce graft versus myeloma effect after cytoreductive autotransplant for multiple myeloma.
    Kroeger, N
    Renges, H
    Krueger, W
    Stute, N
    Zabelina, T
    Schrum, J
    Wittkowsky, G
    Kuse, R
    Hegewisch-Becker, S
    Zander, AR
    BLOOD, 2000, 96 (11) : 782A - 782A
  • [38] Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities
    Korde, Neha
    Mailankody, Sham
    Roschewski, Mark
    Faham, Malek
    Kotwaliwale, Chitra
    Moorhead, Martin
    Kwok, Mary L.
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Tageja, Nishant
    Kazandjian, Dickran
    Costello, Rene
    Zhang, Yong
    Zingone, Adriana
    Burton, Debbie
    Mulquin, Marcia
    Carpenter, Ashley
    Zuchlinski, Diamond
    Lamping, Elizabeth
    Carter, George
    Morrison, Candis
    Kurdziel, Karen
    Lindenberg, Maria
    Kurlander, Roger
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul C.
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Steinberg, Seth M.
    Figg, William D.
    Choyke, Peter
    Landgren, Ola
    BLOOD, 2014, 124 (21)
  • [39] MINIMAL RESIDUAL DISEASE AFTER BMT FOR MULTIPLE-MYELOMA
    BIRD, JM
    SAMSON, D
    RUSSELL, NH
    BLOOD, 1993, 82 (10) : A199 - A199
  • [40] Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
    Costa, Luciano J.
    Chhabra, Saurabh
    Medvedova, Eva
    Dholaria, Bhagirathbhai R.
    Schmidt, Timothy M.
    Godby, Kelly N.
    Silbermann, Rebecca
    Dhaka, Binod
    Bal, Susan
    Gid, Smith
    D'Souza, Anita
    Hall, Aric
    Hardwick, Pamela
    Omel, James
    Cornell, Robert F.
    Had, Parameswaran
    Callander, Natalie S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2901 - +
12345